International Journal of Biology Research

Authors
Samir A Zaahkouk, Amira T Mersal, Rasha A El Sayed, Mona F Abo-El Ezz

Abstract
Background: Chronic hepatitis C virus (HCV) infection is associated with many metabolic complications. Treatment of chronic HCV infection is transitioning from IFN-based to IFN-free regimens that composed of directly acting antiviral (DAA) agents. These DAAs therapy used for patients with a normal range of serum creatinine and glomerular filtration rate. Sofosbuvir (SOF) is one of the highly efficacious and well tolerated DAAs therapy that is primarily eliminated in the urine therefore, poses a challenge for its use in HCV patients with significant renal disease. This study was conducted to monitor the effect of oral treatment of pre-diagnosed HCV patients with 400 mg/d of sofosbuvir for 12 weeks on some kidney functions and cardiac enzymes in concomitant to lipid profile alterations. Results: This study revealed a mild changes in the creatinine levels of both male and female groups, however serum uric acid showed a highly significant increase at male groups. A gradual elevation in the sodium levels were reported in all groups that accompanied with a non-significant increase in the potassium levels. Meanwhile, calcium level showed a significant decrease especially in the female group. A highly significant decrease in the phosphorus level noticed at all studied groups. The treatment-experienced patients with sofosbuvir showed many changes in lipid profile like highly significant increase at total cholesterol level, triglycerides, low-density lipoprotein-cholesterol (LDL-C) and very low-density lipoprotein-cholesterol (VLDL-C) while significant decrease in high-density lipoprotein-cholesterol(HDL-C) at all treated groups were reported. Both of creatine kinase (CK) and Lactate dehydrogenase (LDH) showed a significant decrease in the young female group (IV). On contrary, a significant increase in CK levels at old age male group (III) were revealed. Conclusion: These results suggest that robust studies need to be conducted to confirm the efficacy and safety of sofosbuvir with dose adjustment in patients with renal or cardiac impairments.